Frontiers in Pain Research
2022
Aksharra Balachandran, Vanessa K Tassone, Fathima Adamsahib et al.
Pain and depression frequently co-occur. Due to its antidepressant and analgesic properties, ketamine has been used for the management of treatment-resistant depression and pain. This systematic review examined the literature on the efficacy of sub-anesthetic doses of ketamine in individuals experiencing comorbid depression and chronic pain (CDCP), as well as comorbid depression and acute pain...
Journal of Affective Disorders
2022
Lynnette A. Averill, Christopher L. Averill, Ralitza Gueorguieva et al.
Suicide is a public health crisis with limited treatment options. Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI). The parent study for the secondary pilot analyses presented here was a double-blind, cross-over trial that found pretreatment with the mechanistic target of rapamycin complex 1 (mTORC1) prolonged the antidepressant effects of ketamine. Here we...
Proceedings for Annual Meeting of The Japanese Pharmacological Society
2022
Ryota Shinohara, Brendan Hare, Rong-Jian Liu et al.
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is the prototype for a potential new generation of glutamate-based antidepressants that rapidly relieve symptoms of depression within hours of treatment. Studies in rodents have demonstrated that neuroplasticity in the medial prefrontal cortex (mPFC) is critical for the antidepressant actions of ketamine. However, effector circuits...
Neuroscience of Consciousness
2022
A. Arena, Bjørn E. Juel, R. Comolatti et al.
Abstract It remains unclear how specific cortical regions contribute to the brain’s overall capacity for consciousness. Clarifying this could help distinguish between theories of consciousness. Here, we investigate the association between markers of regionally specific (de)activation and the brain’s overall capacity for consciousness. We recorded electroencephalographic responses to cortical...
Frontiers in Psychiatry
2022
Shannon Dames, Pamela Kryskow, Crosbie Watler
correction
Corrigendum: A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers with PTSD and DepressionError in Figure/TableIn the published article, there was an error in Figure 2 as published. The PTSD label on the legend that is imbedded in the figure was on the legend component of the figure was posted on the anxiety...
Frontiers in Psychiatry
2022
Joshua Willms, Ben McCauley, Lindsay Kerr et al.
Suicide is the most common cause of death in male resident physicians and the second most common cause of death in resident physicians overall. Physicians also experience high rates of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and burnout. These conditions frequently develop during medical school, and threaten not only physicians but the patients they care for. A...
Journal of Affective Disorders
2022
L. Mcinnes, Jimmy J Qian, Rishab Gargeya et al.
60 citations
BACKGROUND Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated. We set out to quantify treatment response to KIT in a large sample of patients from community-based practices. METHODS We retrospectively analyzed 9016 depression patients who received KIT between 2016 and 2020 at one of 178 community practices across the United...
Biochemical and Biophysical Research Communications
2022
Ya-Ting Wang, Ning-Ning Zhang, Ling Liu et al.
47 citations
PURPOSE OF REVIEW To explore the convergent downstream pathways of ketamine and rapastinel and drive further development of identification for following generational rapid-acting antidepressants in the synaptic process. RECENT FINDINGS Ketamine is an NMDAR antagonist and is proven effective in depression for the rapid and sustained antidepressant response, while rapastinel is an NMDAR positive...
Journal of Neurological Sciences
2022
Subha Subramanian, S. Haroutounian, Ben J Palanca et al.
58 citations
Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic...
Psychopharmacology
2022
Edem Ekpenyong Edem, Collins-Kevin Chukwudi Anyanwu, Kate Eberechukwu Nebo et al.
9 citations
Major depressive disorder (MDD) is a serious mental disorder with influence across the functional systems of the body. The pathogenesis of MDD has been known to involve the alteration of normal body functions responsible for the normal inflammation processes within the CNS; this along with other effects results in the depreciation of the sensorimotor performance of the body. Ketamine...